The Global Non-Small Cell Lung Cancer Market size is forecast to reach USD 11.87 Billion by 2028, registering a CAGR of 6.2% over the forecast period, according to a new report by Reports and Data. Major factors driving market revenue growth is the introduction of immune checkpoint inhibitors (ICIs) into the first-line context. Non small cell lung cancer accounts for 80 percent to 85 percent of all lung cancer cases across the world, and this high proportion has prompted the majority of market leaders to focus on constant innovation of new therapies and improving the efficacy of existing medicines. The market growth is also owing to lung cancer's reputation as one of the most common malignancies, contributing to a considerable number of deaths globally. The expansion of the non small cell lung cancer market is further aided by an increase in the frequency of diagnosis of non small cell lung cancer and increased awareness about the disease in developed and emerging countries. This, combined with increased spending by leading companies in research and development operations, as well as the inclusion of non-small cell cancer therapies in major market participants' pipelines, is fueling global market expansion.
One of the challenges of the non-small cell lung cancer market is the high cost of treatment. The disease can be treated by chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy, which is quite expensive. Thus, the high cost of the treatment is expected to restrain growth of the market.
Further key findings from the report suggest
- On the basis of histology the market is segmented into squamous cell carcinoma, large cell carcinoma and adenocarcinoma. Adenocarcinoma held the largest revenue share in the market in 2020. Adenocarcinoma accounts for approximately more than 40% of lung cancer and is found mostly in women and grows more slowly than any other cancers.
- Surgery is expected to grow at a CAGR of 6.8% during the forecast period. Surgery performed at an early stage is the best chance to cure non small cell lung cancer.
- Among the various drug class segments of the market, angiogenesis inhibitor accounted for the largest market share in 2020. It is a substance that inhibits the growth off new blood vessels.
- The market in Asia Pacific is expected account for the largest market revenue share in non-small cell lung cancer market. Rising awareness about cancer and initiatives undertaken by governments in the region will encourage market growth for non-small cell lung cancer. Development of public healthcare centers and subsidized treatment will fuel the market growth.
Top Companies Profiled in the Report Include:
Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.
